Department of Neonatology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
Center for Statistical Science, Peking University, Beijing, China.
PLoS One. 2018 Jul 5;13(7):e0199884. doi: 10.1371/journal.pone.0199884. eCollection 2018.
Preterm birth is associated with increased risk of respiratory symptoms in childhood, often treated with asthma medication. We designed a follow-up study to previous research and investigated whether the association of gestational age with purchasing asthma medication diminishes in adulthood.
We conducted a register-based study of a national cohort of all infants born in Denmark in 1980-2009 evaluating longitudinal data on individually prescribed asthma medication (both inhaled ß-2 receptor agonist and different controller treatment over 2-year periods) available from 1995-2011. We analyzed the effect of gestational age considering age, birth year, and perinatal variables using logistic regression with a Generalized Estimating Equations model. All data were unambiguously linked through the Civil Registration System.
We included 1,819,743 individuals in our study population. We found an inverse dose-response relationship between gestational age and asthma medication in earlier age-groups with a gradual decrease in odds ratios with increasing age and loss of statistical significance in early adulthood (18-31 years). For our oldest generations, there was a significant effect of gestational age (p-value = 0.04), which became insignificant when adjusting for confounding and mediating factors (p = 0.44). There were significant interactions between gestational age and age (p<0.0001) and gestational age and birth year, but these were most important during childhood (0-11 years) and for our youngest generations (born after 1995).
The strong association between gestational age and purchase of prescription asthma medication weakens with age into early adulthood, in consistence with the results from our previous study. The risk for purchasing medication to treat asthma-like symptoms was higher in more recent birth years, but the effect of gestational age was small beyond 11 years of age. Gestational age per se did not seem to be significant for the development of asthma-like symptoms: most of its effect could be explained by other perinatal factors.
早产与儿童期呼吸道症状的风险增加有关,这些症状通常用哮喘药物治疗。我们设计了一项后续研究来跟进之前的研究,并调查胎龄与成年后购买哮喘药物之间的关联是否会减弱。
我们对丹麦 1980-2009 年出生的所有婴儿进行了一项基于登记的队列研究,评估了从 1995-2011 年获得的个人处方哮喘药物(2 年期间吸入β-2 受体激动剂和不同控制器治疗)的纵向数据。我们使用逻辑回归和广义估计方程模型,考虑年龄、出生年份和围产期变量,分析胎龄的影响。所有数据均通过民事登记系统明确关联。
我们的研究人群包括 1819743 人。我们发现,胎龄与哮喘药物之间存在反比剂量反应关系,在年龄较小的年龄组中,随着年龄的增长,比值比逐渐降低,并且在成年早期(18-31 岁)失去统计学意义。对于我们最年长的几代人,胎龄有显著影响(p 值=0.04),但在调整混杂和中介因素后变得不显著(p=0.44)。胎龄与年龄(p<0.0001)和胎龄与出生年份之间存在显著交互作用,但这些作用在儿童期(0-11 岁)和最年轻的几代人(1995 年后出生)中更为重要。
胎龄与处方哮喘药物购买之间的强关联随着年龄进入成年早期而减弱,与我们之前的研究结果一致。在最近的出生年份,购买药物治疗哮喘样症状的风险更高,但胎龄的影响在 11 岁以上很小。胎龄本身似乎对哮喘样症状的发展并不重要:其大部分影响可以用其他围产期因素来解释。